The relentless, focused binding of FOSRENOL.1-4 For sustained phosphate control — meal after meal, day after day, week after week.1, 5, 6
FOSRENOL removes phosphate, removes phosphate, removes phosphate, removes pho
Fosrenol* 500mg, 750mg and 1000mg Chewable
be exercised in these patients, and monitoring of liver function may be required.
oedema; pain; thirst; blood aluminium increased; increase in GGT; increases in
Patients with renal insufﬁ ciency may develop hypocalcaemia. Serum calcium levels
hepatic transaminases; alkaline phosphatase increased; weight decrease.
should therefore be monitored at regular intervals for this patient population and
POM. Marketing Authorisation Holder:
(Please refer to the current full Summary of Product
appropriate supplements given. The risk/beneﬁ t for longer term administration (over
Pharmaceutical Contracts Ltd., Hampshire International Business Park, Chineham,
Characteristics [SmPC] before prescribing) Presentation:
2 years) should be careful y considered as experience with therapy beyond 2 years
Basingstoke, Hampshire RG24 8EP, UK. Marketing Authorisation Number:
containing 500mg, 750mg or 1000mg of lanthanum (as lanthanum carbonate
is limited. Interactions:
Fosrenol may increase gastric pH. Therefore it is
PL 08081/0037-9. Date of Preparation:
January 2007. Further information
hydrate). Excipients are dextrates (hydrated), colloidal anhydrous silica and
recommended that compounds that are known to interact with antacids should not
is available from:
Shire Pharmaceuticals Ltd, Hampshire International Business
magnesium stearate. Indication:
Fosrenol is indicated as a phosphate binding
be taken within 2 hours of dosing with Fosrenol (e.g. chloroquine, hydroxychloroquine
Park, Chineham, Basingstoke, Hampshire RG24 8EP.
FOSRENOL monotherapy is indicated for the control of phosphataemia in chronic renal
agent for use in the control of hyperphosphataemia in chronic renal failure patients
and ketoconazole). Interactions with drugs such as tetracycline, doxycycline and the
failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).
on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Dosage
ﬂ oxacins are theoretically possible. Therefore it is recommended that they are not
Adverse events should be reported to the Yellow Card Scheme.
For oral use. Adults, including elderly (> 65 years):
taken within 2 hours of dosing with Fosrenol. Pregnancy and lactation:
Information about adverse event reporting via this scheme can be
results for up to 6 years of treatment. Nephrol Clin Pract. 2008; 11-(1):c15c23. 2.
should be taken with or immediately after food, with the daily dose divided between
is not recommended in pregnancy. The risk/beneﬁ t for continuing/discontinuing
found at www.yellowcard.gov.uk. Adverse events should also be
et al. Inﬂ uence of Bile Acids on the Phosphate-binding Efﬁ cacy of Lanthanum Carbonate and
meals. The tablets should be chewed and not swallowed whole. The dose of Fosrenol
either Fosrenol or breast feeding should be careful y considered. Undesirable
reported to Shire Pharmaceuticals Ltd on +44 (0)1256 894000.
Sevelamer Hydrochloride. Poster presented at the 38th Annual Meeting of the American
should be titrated every 2-3 weeks until an acceptable serum phosphate level is
effects: Common adverse reactions (>1/100, <1/10 patients)
Healthcare Professionals from other countries should report
Society of Nephrology, Philadelphia, Pennysylvania, 8-13 November 2005. 3.
reached. Control of serum phosphate level has been demonstrated at doses starting
gastrointestinal reactions (such as abdominal pain, constipation, diarrhoea,
adverse events in accordance with their local requirements.
Summary of Product Characteristics, 2007. 4.
Finn et al. 25-hydroxyvitamin D and
from 750mg. The maximum daily dose studied, in a limited number of patients, is
dyspepsia, ﬂ atulence, nausea and vomiting); hypocalcaemia. Uncommon adverse
1,25-dihydroxyvitamin D levels in patients with CKD Stages 3 and 4 are not affected by
3750mg. Patients who respond to lanthanum therapy usually achieve acceptable
reactions (>1/1000, <1/100 patients)
include gastroenteritis; laryngitis;
The prescribing information above is for the UK. Product presentations and
lanthanum carbonate: results from a randomized multicentre trial. 5.
Hutchison AJ, Maes B,
serum phosphate levels at doses of 1500-3000mg lanthanum per day. Children and
eosinophilia; hyperparathyroidism; hypercalcaemia; hyperglycaemia; indications may differ from those in your own country. Please consult your local
Vanwal eghem J, et al. Long-term efﬁ cacy and tolerability of lanthanum carbonate: results
Adolescents (< 18 years):
Not recommended. Contra-indications:
hyperphosphataemia; hypophosphataemia; anorexia; appetite increased; dizziness;
from a 3-year study. Nephrol Clin Pract. 2006; 102(2):c61-c71. 6.
Finn WF; on behalf of
to lanthanum carbonate hydrate or to any of the excipients. Hypophosphataemia.
headache; taste alteration; vertigo; eructation; indigestion; irritable bowel syndrome;
the SDP 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy
Special warnings and precautions:
Patients with acute peptic ulcer, ulcerative
dry mouth; oesophagitis; stomatitis; loose stools; tooth disorder; gastrointestinal
for the treatment of hyperphosphatemia: safety and efﬁ cacy in chronic maintenance
colitis, Crohn’s disease or bowel obstruction were not included in clinical studies with
disorder NOS; alopecia; itching; pruritus; erythematous rash; sweating increased;
Hutchison AJ, Barnet ME, Krause R, Kwan JT, Siami GA; on behalf of the SPD405-309
hemodialysis patients. Clin Nephrol. 2006; 65(3): 191-202.
Fosrenol. No data is available in patients with hepatic impairment. Caution should
arthralgia; myalgia; osteoporosis; asthenia; chest pain; fatigue; malaise; peripheral
Lanthanum Study Group. Long-term efﬁ cacy and safety proﬁ le of lanthanum carbonate:
Date of preparation: July 2009. Item no: INT/FOS/09/0016.
E F F EC T O F B I S O P R O L O L O N M O R B I D I T Y A N D M O R TA L I T Y I N PAT I E N T S U N D E R G O I N G VAS C U L A R S U R G E RY THE EFFECT OF BISOPROLOL ON PERIOPERATIVE MORTALITY AND MYOCARDIAL INFARCTION IN HIGH-RISK PATIENTS UNDERGOING VASCULAR SURGERY DON POLDERMANS, PH.D., ERIC BOERSMA, PH.D., JEROEN J. BAX, PH.D., IAN R. THOMSON, PH.D.,LO
Minutes of the Regular Village Board Meeting Held April 24, 2012 The Board of Trustees of the Village of Mt. Morris met in Regular Session in the Board Room of the Village Hall in said Village at 7:00 PM on Tuesday April 24, 2012. The President called the meeting to order and directed the Village Clerk to call the roll. Upon roll being called, the following answered present: Don Sorensen, J